论文部分内容阅读
目的 观察白介素 2合并生脉注射液治疗肝癌栓塞化疗后近期疗效、生存率及免疫功能变化等临床指标。方法 采用已确诊的原发性及转移性肝癌 14 4例 ,随机分为治疗组及对照组各 72例 ,治疗组在采用肝癌栓塞化疗后即用白介素 2 2 0万U肌注 ,5 %GS2 5 0ml +生脉注射液 40ml静脉滴注 ,1/日 ,10～ 15天为 1疗程。对照组仅作栓塞化疗 ,两组病人行栓塞化疗 2～ 6次不等 ,间隔时间视病情而定。结果 治疗组有效率 (CR +PR)为 84.7( 61/72 ) ,明显高于对照组( 5 8.3 % ,42 /72 ) ;治疗组 1年、2年、3年生存率分别为 80 .5 %、66.7%、3 5 .4% ,中位生存期为 18个月 ,而对照组分别为 47.2 %、3 1.9%、13 .8% ,中位生存期为 10个月。两组比较有非常显著性差异 (P <0 .0 1) ;自然杀伤细胞 (NK)活性、T细胞亚群 (CD3 、CD4 、CD8、CD4 /CD4 )数值 ,在治疗后治疗组明显提高 ,对照组下降 ,两组有显著差异性 (P <0 .0 5 )。结论 生脉注射液联合白介素 2治疗肝癌栓塞化疗 ,有效率、生存率、中位生存期、免疫指标均较单纯栓塞化疗为高 ,是治疗中晚期肝癌较理想的方法。
Objective To observe the clinical efficacy of interleukin-2 combined with Shengmai injection in the treatment of liver cancer after thromboembolism and short-term curative effect, survival rate and immune function changes. Methods A total of 144 cases of primary and metastatic HCC were identified and randomly divided into treatment group (72 cases) and control group (72 cases). The treatment group received 20 million UU interleukin (IL) injection, 5% GS2 5 0ml + Shengmai injection 40ml intravenous infusion, 1 / day, 10 to 15 days for a course of treatment. Control group only for embolic chemotherapy, two groups of patients embolization chemotherapy 2 to 6 times, depending on the time interval may be. Results The effective rate (CR + PR) of the treatment group was 84.7 (61/72), which was significantly higher than that of the control group (53.3%, 42/72). The 1-year, 2-year and 3-year survival rates of the treatment group were 80.5 %, 66.7%, 35.4% respectively. The median survival time was 18 months, while the control group was 47.2%, 3 1.9% and 13.8% respectively. The median survival time was 10 months. There were significant differences between the two groups (P <0.01); NK activity and T cell subsets (CD3, CD4, CD8, CD4 / CD4) The control group decreased, there was significant difference between the two groups (P <0.05). Conclusion Shengmai injection combined with interleukin-2 in the treatment of liver cancer embolization chemotherapy, effective rate, survival rate, median survival, immune index than simple embolization chemotherapy is high, is the treatment of advanced liver cancer more ideal method.